G5-PEG PAMAM dendrimer incorporating nanostructured lipid carriers enhance oral bioavailability and plasma lipid-lowering effect of probucol

Journal of Controlled Release

Volumn 210, Issue , 2015, Pages 160-168

  Qi, Rong ^a,b   Li, Yan Zhi ^a,b,c   Chen, Cong ^a,b   Cao, Yi Ni ^a,b   Yu, Mao Mao ^a,b   Xu, Lu ^a,b   He, Bing ^a   Jie, Xu ^a,b   Shen, Wen Wen ^a,b   Wang, Yu Nan ^a,b   Van Dongen, Mallory A ^d   Liu, Guo Qing ^a,b   Banaszak Holl, Mark M ^d   Zhang, Qiang ^a   Ke, Xue ^c  

^a PEKING UNIVERSITY HEALTH SCIENCE CENTER   (China)

^b BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^c CHINA PHARMACEUTICAL UNIVERSITY   (China)

^d UNIVERSITY OF MICHIGAN   (United States)

Author keywords

Lipid lowering effect; Nanostructured lipid carriers; Oral bioavailability; PEG PAMAM dendrimers; Probucol; Water solubility

Indexed keywords

ACETONE; CELLS; DENDRIMERS; ENCAPSULATION; HYDROPHOBICITY; MOBILE SECURITY; PARTICLE SIZE; SOLUBILITY; SUSPENSIONS (FLUIDS);

LIPID-LOWERING EFFECTS; NANOSTRUCTURED LIPID CARRIERS; ORAL BIOAVAILABILITIES; PAMAM DENDRIMER; PROBUCOL; WATER SOLUBILITIES;

BIOCHEMISTRY;

CHOLESTEROL; DENDRIMER; GENERATION OF 5 POLYETHYLENE GLYCOL POLYAMIDOAMINE; LIPID; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROGOL; POLYAMIDOAMINE; POLYMER; PROBUCOL; UNCLASSIFIED DRUG; DRUG CARRIER; HYPOCHOLESTEROLEMIC AGENT; MACROGOL DERIVATIVE; NANOMATERIAL; PEG-PAMAM;

ANIMAL EXPERIMENT; ANIMAL MODEL; AQUEOUS SOLUTION; AREA UNDER THE CURVE; ARTICLE; CACO 2 CELL LINE; CELL TRANSPORT; CELL VIABILITY; CONTROLLED STUDY; CYTOTOXICITY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DEGRADATION; DRUG DELIVERY SYSTEM; DRUG EFFECT; DRUG FORMULATION; DRUG MECHANISM; DRUG RELEASE; DRUG SOLUBILITY; DRUG STABILITY; DRUG STORAGE; DRUG UPTAKE; ENCAPSULATION; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; IN VIVO STUDY; LIPID BLOOD LEVEL; MALE; MAXIMUM PLASMA CONCENTRATION; MOLECULAR WEIGHT; MORPHOLOGY; MOUSE; NONHUMAN; PARTICLE SIZE; PLASMA; PRIORITY JOURNAL; SINGLE DRUG DOSE; SUSPENSION; THERMOSTABILITY; TIME TO MAXIMUM PLASMA CONCENTRATION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; BLOOD; CHEMISTRY; GENETICS; KNOCKOUT MOUSE; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANIMALS; ANTICHOLESTEREMIC AGENTS; BIOLOGICAL AVAILABILITY; CACO-2 CELLS; DENDRIMERS; DRUG CARRIERS; DRUG LIBERATION; HUMANS; LIPIDS; MALE; MICE, KNOCKOUT; NANOSTRUCTURES; POLYETHYLENE GLYCOLS; PROBUCOL; RECEPTORS, LDL;

EID: 84930201170     PISSN: 01683659     EISSN: 18734995     Source Type: Journal    
DOI: 10.1016/j.jconrel.2015.05.281     Document Type: Article

References (27)

1. S. Yamashita, and Y. Matsuzawa Where are we with probucol: a new life for an old drug? Atherosclerosis 207 2009 16 23
2. M.M. Buckley, K.L. Goa, A.H. Price, and R.N. Brogden Probucol. A reappraisal of its pharmacological properties and therapeutic use in hypercholesterolaemia Drugs 37 1989 761 800
3. S. Yamashita, H. Hbujo, H. Arai, M. Harada-Shiba, S. Matsui, M. Fukushima, Y. Saito, T. Kita, and Y. Matsuzawa Long-term probucol treatment prevents secondary cardiovascular events: a cohort study of patients with heterozygous familial hypercholesterolemia in Japan J. Atheroscler. Thromb. 15 2008 292 303
4. Y.T. Naomi Yagi Harumi Kenmotsu, Hitoshi Sekikawa, Masahiko Takada, Dissolution behavior of probucol from solid dispersion systems of probucol polyvinylpyrrolidone Chem. Pharm. Bull. 44 1996 241 244
5. Y. Kubo, Y. Terashima, N. Yagi, H. Nochi, K. Tamoto, and H. Sekikawa Enhanced bioavailability of probucol following the administration of solid dispersion systems of probucol-polyvinylpyrrolidone in rabbits Biol. Pharm. Bull. 32 2009 1880 1884
6. E. Ishida, C. Managit, S. Kawakami, M. Nishikawa, F. Yamashita, and M. Hashida Biodistribution characteristics of galactosylated emulsions and incorporated probucol for hepatocyte-selective targeting of lipophilic drugs in mice Pharm. Res. 21 2004 932 939
7. X. Lin, X. Li, L. Zheng, L. Yu, Q. Zhang, and W. Liu Preparation and characterization of monocaprate nanostructured lipid carriers Colloids Surf. A Physicochem. Eng. Asp. 311 2007 106 111
8. E.B. Souto, S.A. Wissing, C.M. Barbosa, and R.H. Muller Development of a controlled release formulation based on SLN and NLC for topical clotrimazole delivery Int. J. Pharm. 278 2004 71 77
9. R. Esfand, and D.A. Tomalia Poly(amidoamine) (PAMAM) dendrimers: from biomimicry to drug delivery and biomedical applications Drug Discov. Today 6 2001 427 436
10. E.R. Gillies, and J.M. Frechet Dendrimers and dendritic polymers in drug delivery Drug Discov. Today 10 2005 35 43
11. G. Purohit, T. Sakthivel, and A.T. Florence Interaction of cationic partial dendrimers with charged and neutral liposomes Int. J. Pharm. 214 2001 71 76
12. K. Gardikis, C. Tsimplouli, K. Dimas, M. Micha-Screttas, and C. Demetzos New chimeric advanced Drug Delivery nano Systems (chi-aDDnSs) as doxorubicin carriers Int. J. Pharm. 402 2010 231 237
13. K.N. Kontogiannopoulos, A.N. Assimopoulou, S. Hatziantoniou, K. Karatasos, C. Demetzos, and V.P. Papageorgiou Chimeric advanced drug delivery nano systems (chi-aDDnSs) for shikonin combining dendritic and liposomal technology Int. J. Pharm. 422 2012 381 389
14. R. Qi, H. Zhang, L. Xu, W. Shen, C. Chen, C. Wang, Y. Cao, Y. Wang, M.A. van Dongen, B. He, S. Wang, G. Liu, M.M. Banaszak Holl, and Q. Zhang G5 PAMAM dendrimer versus liposome: a comparison study on the in vitro transepithelial transport and in vivo oral absorption of simvastatin Nanomed. Nanotechnol. Biol. Med. 11 2015 1141 1151
15. Q. Ma, Y. Han, C. Chen, Y. Cao, S. Wang, W. Shen, H. Zhang, Y. Li, M.A. van Dongen, B. He, M. Yu, L. Xu, M.M. Banaszak Holl, G. Liu, Q. Zhang, and R. Qi Oral absorption enhancement of probucol by PEGylated G5 PAMAM dendrimer modified nanoliposomes Mol. Pharm. 12 2015 665 674
16. M. Jedrych, K. Borowska, R. Galus, and B. Jodlowska-Jedrych The evaluation of the biomedical effectiveness of poly(amido)amine dendrimers generation 4.0 as a drug and as drug carriers: a systematic review and meta-analysis Int. J. Pharm. 462 2014 38 43
17. R. Qi, Y. Gao, Y. Tang, R.R. He, T.L. Liu, Y. He, S. Sun, B.Y. Li, Y.B. Li, and G. Liu PEG-conjugated PAMAM dendrimers mediate efficient intramuscular gene expression AAPS J. 11 2009 395 405
18. P. Kolhe, E. Misra, R.M. Kannan, S. Kannan, and M. Lieh-Lai Drug complexation, in vitro release and cellular entry of dendrimers and hyperbranched polymers Int. J. Pharm. 259 2003 143 160
19. J.Z. Duan, K. Riviere, and P. Marroum In vivo bioequivalence and in vitro similarity factor (f2) for dissolution profile comparisons of extended release formulations: how and when do they match? Pharm. Res. 28 2011 1144 1156
20. M.V. Berridge, and A.S. Tan Characterization of the cellular reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT): subcellular localization, substrate dependence, and involvement of mitochondrial electron transport in MTT reduction Arch. Biochem. Biophys. 303 1993 474 482
21. A. Papagiannaros, K. Dimas, G.T. Papaioannou, and C. Demetzos Doxorubicin-PAMAM dendrimer complex attached to liposomes: cytotoxic studies against human cancer cell lines Int. J. Pharm. 302 2005 29 38
22. K. Gardikis, S. Hatziantoniou, M. Bucos, D. Fessas, M. Signorelli, T. Felekis, M. Zervou, C.G. Screttas, B.R. Steele, M. Ionov, M. Micha-Screttas, B. Klajnert, M. Bryszewska, and C. Demetzos New drug delivery nanosystem combining liposomal and dendrimeric technology (liposomal locked-in dendrimers) for cancer therapy J. Pharm. Sci. 99 2010 3561 3571
23. K.M. Kitchens, M.E. El-Sayed, and H. Ghandehari Transepithelial and endothelial transport of poly (amidoamine) dendrimers Adv. Drug Deliv. Rev. 57 2005 2163 2176
24. C.L. Chang, C. Torrejon, U.J. Jung, K. Graf, and R.J. Deckelbaum Incremental replacement of saturated fats by n - 3 fatty acids in high-fat, high-cholesterol diets reduces elevated plasma lipid levels and arterial lipoprotein lipase, macrophages and atherosclerosis in LDLR -/- mice Atherosclerosis 234 2014 401 409
25. D.S. Goldberg, N. Vijayalakshmi, P.W. Swaan, and H. Ghandehari G3.5 PAMAM dendrimers enhance transepithelial transport of SN38 while minimizing gastrointestinal toxicity J. Control. Release 150 2011 318 325
26. Y. Lin, T. Fujimori, N. Kawaguchi, Y. Tsujimoto, M. Nishimi, Z. Dong, H. Katsumi, T. Sakane, and A. Yamamoto Polyamidoamine dendrimers as novel potential absorption enhancers for improving the small intestinal absorption of poorly absorbable drugs in rats J. Control. Release 149 2011 21 28
27. K.M. Kitchens, R.B. Kolhatkar, P.W. Swaan, and H. Ghandehari Endocytosis inhibitors prevent poly(amidoamine) dendrimer internalization and permeability across Caco-2 cells Mol. Pharm. 5 2008 364 369